Neurofibromatosis type 1 is a multisystem genetic disorder associated with an increased risk of benign and malignant tumors due to mutations in the NF1 gene. Clinical manifestations of the disease vary and depend on the patient’s age. One of the most common complications of neurofibromatosis type 1 is plexiform neurofibroma – a benign tumor affecting peripheral nerves. For a long time, there had been no standard care for such patients in the Russian Federation; treatment of plexiform neurofibromas was usually limited to symptomatic therapy and repeated surgical interventions. In the last few years, treatment approach to patients with neurofibromatosis type 1 complicated by plexiform neurofibromas changed, since a targeted drug, selumetinib became available. In clinical trials, 65 % of children receiving selumetinib demonstrated a partial response (reduction in the volume of plexiform neurofibromas by 20 % or more) for more than 3 cycles (months), 56 % of children demonstrated a long-term response (a year or more) without traumatic surgical interventions. In our country, more than 200 children have already received selumetinib under the early access program after its registration in the Russian Federation (January 2021). In Yu.E. Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery, the drug was prescribed to 104 patients; of them, 54 patients were followed up between April 2021 and October 2023. The most common adverse events associated with selumetinib in our patients included skin rash (acne/maculopapular rash or eczema), dry skin, hair discoloration and hair loss, paronychia, and an asymptomatic elevation of creatine phosphokinase. This article provides information on the most common adverse events of selumetinib therapy, preventive measures, and recommendations for patient follow-up.
15 December 2023 in Pediatria. Journal named after G.N. Speransky
Geroderma osteodysplasticum (OMIM #231070) is a rare autosomal recessive disorder characterized by congenital wrinkled skin on the dorsal surface of the limbs and abdomen; marked osteoporosis in childhood. Pathogenic variants of the nucleotide sequence in the GORAB gene, which encodes the GORAB protein located in the Golgi apparatus and plays a crucial role in vesicle transport in the Golgi complex, lead to the disease. This is the first report of 2 patients with this disease in Russia. A detailed description of the clinical-radiological and genetic characteristics of these patients with new nucleotide variants in the GORAB gene in a compound heterozygous state is presented: c.170C>G (p.Ser57Ter) and c.790G>C (p.Ala264Pro); c.295C>T (p.Gln99Ter) and heterozygous deletion on chromosome 1 (chr1:g.170531967–170539494del), affecting exons 1 and 2 of the gene. The main clinical manifestations of the syndrome were congenital wrinkled skin, sagging cheeks, hypoplasia of the cheekbones, prognathism, muscle hypotonia and joint hypermobility. Radiological signs included congenital bilateral dislocation of the hip, compression fractures of the vertebral bodies, and disruption of the continuity of the growth plate of the distal femur and proximal tibia, referred to as “insertion.” The rarity of the syndrome, as well as the similarity of clinical manifestations with a heterogeneous group of hereditary diseases accompanied by decreased skin elasticity, leads to a late correct diagnosis. This necessitates the description of the clinical-genetic characteristics of the disease, the study of the dynamics of the formation of its phenotypic manifestations, and the methods of molecular-genetic diagnostics.
25 April 2026 in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
Loeys-Dietz syndrome is a monogenic connective tissue disease with an autosomal dominant inheritance pattern. The TGFBR1, TGFBR2, TGFB2, TGFB3, SMAD2, and SMAD3 genes, which are associated with six types of the syndrome, encode components of the transforming growth factor β (TGFβ) signaling pathway. The pathogenesis of the syndrome is associated with impaired signal transmission in this signaling pathway, which leads to impaired structure and function of the connective tissue elements in many organs and systems, including the cardiovascular, respiratory, musculoskeletal, central nervous, and visual systems. The article presents an analysis of the medical histories of 7 children with types 1 and 2 of Loeys-Dietz syndrome, which was confirmed by molecular genetics (mutations in the TGFBR1 and TGFBR2 genes). All 7 probands had cardiovascular and musculoskeletal disorders, as well as allergic manifestations. It was noted that all patients had abnormalities in their urinary system. The clinical data of a child who inherited the disease from an ill mother are provided in detail. A differential diagnosis was performed with other phenotypically similar monogenic connective tissue diseases. It is emphasized that medical supervision of patients with Loeys-Dietz syndrome should be carried out with the participation of a clinical geneticist, cardiac and orthopedic surgeons, a nephrologist, an allergist, and an ophthalmologist. The insufficient effectiveness of medical and cardiac surgical methods highlights the importance of developing a pathogenetic therapy for this severe disease.
24 December 2024 in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
Pathogenic nucleotide variants in the MORC2 gene have recently been linked to axonal peripheral neuropathy (Charcot–Marie–Tooth disease, axonal type 2Z) and the syndrome of developmental and growth disorders, facial dysmorphia, and axonal neuropathy (DIGFAN syndrome). DIGFAN syndrome is marked by early onset and multisystem symptoms, particularly affecting the visual and auditory organs. In approximately 30% of cases, mitochondrial encephalomyopathy is initially considered a possible diagnosis. In a girl with a heterozygous MORC2 gene mutation, the presence of DIGFAN syndrome was confirmed. Her clinical profile included motor, speech, and physical developmental delays, along with visual and auditory impairments, peripheral neuropathy, facial dysmorphia, Lee-like changes on MRI, and moderate lactic acidemia. Following metabolic therapy targeting intracellular energy exchange processes, alongside a rehabilitation program, some improvement in her condition and normalization of blood lactate levels were observed. The importance of early diagnosis is highlighted, as it supports the timely initiation of metabolic therapy and other therapeutic interventions under specialist supervision. Confirming the diagnosis is critical for anticipating disease progression and providing genetic counseling for the proband and their family.